• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Ignelzi Troy A.

    6/26/25 5:44:32 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTNM alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Ignelzi Troy A.

    (Last) (First) (Middle)
    3565 GENERAL ATOMICS COURT, SUITE 200

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Contineum Therapeutics, Inc. [ CTNM ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/26/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $4.01 06/26/2025 A 14,750 (1) 06/25/2035 Class A Common Stock 14,750 $0 14,750 D
    Explanation of Responses:
    1. Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.
    /s/ Peter Slover, Attorney-in-Fact 06/26/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CTNM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CTNM

    DatePrice TargetRatingAnalyst
    6/20/2025Outperform
    William Blair
    10/22/2024$32.00Outperform
    Robert W. Baird
    More analyst ratings

    $CTNM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Contineum Therapeutics

      William Blair initiated coverage of Contineum Therapeutics with a rating of Outperform

      6/20/25 7:53:37 AM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Contineum Therapeutics with a new price target

      Robert W. Baird initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $32.00

      10/22/24 6:13:41 AM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced an update on its Phase 1b positron emission tomography (PET) trial of PIPE-791, a selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor. The Company has completed enrollment of the healthy volunteer and progressive multiple sclerosis (PrMS) cohorts of this trial. The screening and enrollment of idiopathic pulmonary fibrosis (IPF) patients to participate in this trial is ongoing. "In early June, consistent with our protocol, we enr

      6/25/25 8:15:00 AM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair

      ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery, announced several business updates. First, the company has raised the next round of financing to advance its pipeline and continue to expand the scope and capabilities of its discovery platform. The Boehringer Ingelheim Venture Fund led the financing, which also included existing investors Insight Partners, Innospark, and Nor'easter Ventures, and new investor AB Magnitude. "We are grateful for the ongoing support of our strong investor base and welcome our new investor, AB Magni

      6/23/25 8:45:00 PM ET
      $ARTV
      $CTNM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th at 8:30 a.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Contineum's website. A webcast replay will also be available. About Contineum Therapeutics Contineum Therapeutics (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI

      5/15/25 4:05:00 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Boyce Sarah

      4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

      6/26/25 5:50:00 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Schimmelpennink Evert B.

      4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

      6/26/25 5:47:53 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Brady Todd R.

      4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

      6/26/25 5:46:34 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Leadership Updates

    Live Leadership Updates

    See more
    • Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

      4/28/25 4:05:00 PM ET
      $CTNM
      $GILD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025. "We are excited to welcome Diego to our board," commented Eef Schimmelpennink, Contineum's Chairperson. "He has successfully led the development of novel therapies throughout his distinguished career and has an extensive track record in both early stage research and all stages of clinical development. During his time at Janssen Research, Dr.

      3/17/25 4:05:00 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

      SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. "We are pleased to welcome Lori as chair of the board," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "In the four years that Lori has served as a board membe

      1/6/25 8:00:00 AM ET
      $CTNM
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Contineum Therapeutics Inc.

      SC 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)

      11/14/24 4:38:16 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    SEC Filings

    See more
    • Contineum Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)

      6/26/25 4:07:21 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Contineum Therapeutics Inc.

      EFFECT - Contineum Therapeutics, Inc. (0001855175) (Filer)

      5/27/25 12:15:13 AM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Contineum Therapeutics Inc.

      SCHEDULE 13G/A - Contineum Therapeutics, Inc. (0001855175) (Subject)

      5/15/25 4:30:16 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care